Blog

A closer look at mesenchymal stem cells and their potential in the arthritic joint.

For millions of people living with arthritis, the story often begins with familiar symptoms: stiffness, swelling, pain and a gradual loss of movement.

But arthritis is more than simple “wear and tear”.

Within an affected joint, multiple tissues and biological processes can become disrupted. In osteoarthritis particularly, cartilage can deteriorate, changes can occur in the underlying bone, inflammatory signals can increase, and the synovial lining and surrounding tissues can become damaged. Rather than being a problem confined to cartilage, osteoarthritis is increasingly understood as a condition affecting the joint as a whole.

Current osteoarthritis treatments focus on reducing symptoms, maintaining mobility and function, and helping people manage the condition. These approaches can be highly effective, but they do not necessarily reverse the underlying structural changes within the joint.

A new area of cell-based science is looking beyond symptom management and towards the biology of the joint itself.

One of the cells at the centre of this field is the mesenchymal stem cell (MSC).

What are mesenchymal stem cells?

MSCs are naturally occurring cells found in a variety of tissues throughout the body. They can be sourced from areas including bone marrow, adipose tissue, umbilical cord, placenta and other connective tissues.

MSCs are particularly interesting because of their ability to interact with the environment around them.

Rather than thinking of MSCs simply as replacement cells, it may be more useful to think of them as biological coordinators that communicate with their neighbouring cells and influence the local tissue environment.

MSCs can release a range of signalling molecules and other factors that may influence inflammation, immune responses, cell activity and tissue repair processes. Through these interactions, MSCs may have the capacity to affect several aspects of the joint environment at once.

This is an important distinction. Their potential may not depend solely on whether they become new tissue-forming cells, but also on how they communicate with and influence the cells that are already present.

The cartilage connection

Cartilage is one of the most important structures in a healthy joint.

It is remarkably good at one thing – providing a smooth, cushioning surface that allows our joints to move. Unfortunately, it isn’t nearly as good at repairing itself.

As osteoarthritis progresses, the balance between cartilage breakdown and repair can become increasingly unfavourable.

MSCs have attracted attention in this area for two related reasons.

First, under appropriate experimental conditions, MSCs can differentiate towards cartilage-producing cell types. Second, they can release signalling factors that may influence the behaviour of cells within the surrounding tissue.

This means their potential role may extend beyond simply replacing cells that have been lost.

Instead, MSCs could help create a more supportive environment for tissue maintenance and repair.

More than cartilage repair

Perhaps one of the most interesting aspects of MSC biology is that their potential isn’t limited to cartilage.

An arthritic joint is a dynamic biological environment.

Inflammatory signals within the joint can contribute to changes in cartilage and surrounding tissues, creating an environment that favours ongoing tissue damage.

MSCs have immunomodulatory properties, meaning they can interact with immune cells and influence aspects of the inflammatory response. They also respond to signals within their local environment, which may affect how they behave and what factors they release.

This raises an important possibility: rather than targeting cartilage alone, MSC-based approaches could potentially influence several components of the joint environment simultaneously.

That multi-faceted biology is one of the reasons MSCs are being investigated in osteoarthritis and other musculoskeletal conditions.

Rethinking the joint as an ecosystem

A joint is not simply a collection of separate structures. Cartilage, bone, synovial tissue, ligaments, tendons and the cells within these tissues interact continuously. Changes in one part of the joint can influence what happens elsewhere.

From this perspective, the question is no longer simply:

How do we replace damaged cartilage?

It becomes:

How can we influence the biological environment in which the joint’s tissues are maintained, damaged and repaired?

This is where the biology of MSCs becomes particularly interesting.

Their potential effects may involve several interconnected mechanisms:

• Cellular communication: releasing signals that can influence neighbouring cells and their activity.

• Immune modulation: interacting with immune cells and pathways involved in inflammation.

• Tissue support: influencing the local environment in ways that may support tissue maintenance and repair.

• Cartilage-related activity: under appropriate conditions, differentiating towards cartilage-forming cell types.

• Response to the local environment: responding to signals associated with tissue injury, inflammation and changes within the joint.

These properties suggest that MSCs may be better understood not simply as “replacement cells”, but as cells capable of interacting with and potentially influencing the wider tissue environment.

From symptom management to biological support

For decades, the primary goal of arthritis treatment has been to reduce symptoms, preserve function, and help people maintain quality of life.

Cell-based approaches introduce an additional area of investigation: whether it may be possible to influence some of the biological processes occurring within the joint itself.

MSCs offer an intriguing combination of characteristics. They can interact with damaged or inflamed tissue, communicate with surrounding cells, modulate aspects of the immune response, and contribute to processes associated with tissue repair.

But this does not make MSCs a simple replacement for damaged cartilage, nor does it mean that they are a proven cure for osteoarthritis.

Their potential may lie in something more nuanced: influencing the environment in which the joint’s own cells function.

That distinction is important as research continues to develop.

What could the future of joint care look like?

The next generation of arthritis treatments may not be defined by a single drug, injection or procedure.

Instead, treatment could increasingly involve approaches tailored to the biology of an individual joint — taking into account factors such as the extent of tissue damage, inflammatory activity, disease stage and the capacity of the surrounding tissues to respond.

MSCs offer a glimpse into what the future could look like: moving from simply managing the consequences of arthritis towards supporting the biological processes that influence joint health.

The future of arthritis treatment may not only be about protecting what remains. It may be about creating the right environment for the body to do more with what it already has.

References

1. Wu K-C, Chang Y-H, Ding D-C, et al. Mesenchymal Stromal Cells for Aging Cartilage Regeneration: A Review. International Journal of Molecular Sciences. 2024;25(23):12911.
2. Tian X, Qu Z, Cao Y, Zhang B. Relative efficacy and safety of mesenchymal stem cells for osteoarthritis: a systematic review and meta-analysis of randomized controlled trials. Frontiers in Endocrinology. 2024;15:1366297.
3. Tabet CG, et al. Advanced therapy with mesenchymal stromal cells for knee osteoarthritis: Systematic review and meta-analysis of randomized controlled trials. Journal of Orthopaedic Translation. 2024;48:176–189.
4. Sadeghirad B, et al. Mesenchymal stem cells for chronic knee pain secondary to osteoarthritis: A systematic review and meta-analysis of randomized trials. Osteoarthritis and Cartilage. 2024;32(10):1207–1219.
5. Zeng L, et al. Efficacy and safety of culture-expanded mesenchymal stromal cell therapy in the treatment of 4 types of inflammatory arthritis: A systematic review and meta-analysis of 36 randomized controlled trials. Seminars in Arthritis and Rheumatism. 2024;68:152498.